THE EFFICACY OF LINAGLIPTIN IN TYPE 2 DIABETES MELLITUS PATIENT WITH DIFFERENT RENAL INSUFFICIENT IN A REGIONAL HOSPITAL OF NORTHERN TAIWAN.
- At: 2015 FIP Congress in Düsseldorf (Germany)
- Type: Poster
- By: WANG, Hsing-Hui (Sijhih Cathay General Hospital, Pharmacy, Taipei, China Taiwan)
- Co-author(s): Yu-Li LIN
Linagliptin is the first dipeptidyl peptidase-4 (DPP-4) inhibitor which does not need dose adjustiment in type 2 diabetes mellitus (T2DM) with any degree of renal function impairment because of hepatobiliary elimination.
We retrospectively analyze data derived from a local hospital in the period of April 2013 till March 2015. According to renal.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.